Literature DB >> 2823095

Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis.

I Votruba1, R Bernaerts, T Sakuma, E De Clercq, A Merta, I Rosenberg, A Holý.   

Abstract

The acyclic nucleotide analogue (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)-adenine [(S)-HPMPA], which contains a phosphonate-substituted aliphatic chain, is a potent and selective inhibitor of the replication of various DNA viruses, including herpes simplex virus type 1 (HSV-1). We have synthesized radiolabeled (S)-[U-14C-adenine]HPMPA and investigated its metabolism by HSV-1-infected and mock-infected cells. The drug is as such taken up by the cells and subsequently converted to its monophosphoryl [(S)-HPMPAp] and diphosphoryl [(S)-HPMPApp] derivatives by cellular enzymes. It is incorporated to a very low extent into DNA of both mock-infected and HSV-1-infected Vero cells. (S)-HPMPA inhibits HSV-1 DNA synthesis at a concentration that is several orders of magnitude lower than the concentration required for inhibition of cellular DNA synthesis. Thus the selectivity of (S)-HPMPA as an antiviral agent cannot be attributed to a differential phosphorylation by virus-infected or uninfected cells but resides in a specific inhibitory effect on viral DNA synthesis. The exact basis for the latter effect is under investigation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823095

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

2.  Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.

Authors:  F S Stals; E de Clercq; C A Bruggeman
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.

Authors:  E De Clercq; A Holý; I Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.

Authors:  G Andrei; R Snoeck; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

5.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.

Authors:  E De Clercq; A Holý
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 6.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

7.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

8.  Antiviral activity of oxetanocins against varicella-zoster virus.

Authors:  T Sakuma; M Saijo; T Suzutani; I Yoshida; S Saito; M Kitagawa; S Hasegawa; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.

Authors:  Sanaa Botros; Samia William; Olfat Hammam; Zdenĕk Zídek; Antonín Holý
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.